New drug shows promise in reducing lung scarring in small trial

NCT ID NCT05621252

Completed Disease control Sponsor: Pliant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2a trial tested a drug called PLN-74809 in 10 people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. Participants took the drug or a placebo daily for 12 weeks. The study used a special PET/MRI scan to measure collagen (scar tissue) in the lungs. The goal was to see if the drug could reduce scarring and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PLN-74809 (a drug to reduce lung scarring)
What this could lead to: If successful, this could point toward a treatment that slows or reduces scarring in the lungs for people with idiopathic pulmonary fibrosis.
What could go wrong: This is a very small, early-phase trial with only 10 participants. It is designed mainly to test imaging and safety, not yet to prove the drug works. The drug may not show benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.